CDK Inhibitor

By Targets:	CDK (408) Akt (3) AMPK (1) Amyloid-β (1) Anaplastic lymphoma kinase (ALK) (1) Angiotensin-converting Enzyme (ACE) (1) Antibiotic (1) Apoptosis (74) ATM/ATR (2) Aurora Kinase (2) Autophagy (10) Bacterial (2) Bcl-2 Family (2) c-Kit (1) c-Met/HGFR (1) c-Myc (1) Calcium Channel (1) Carbonic Anhydrase (4) Casein Kinase (5) Caspase (3) CFTR (1) Checkpoint Kinase (Chk) (2) Cholinesterase (ChE) (1) CMV (2) COX (1) Cyclin G-associated Kinase (GAK) (2) DAPK (1) DNA/RNA Synthesis (2) Drug Metabolite (2) DYRK (2) Early 2 Factor (E2F) (1) EGFR (14) Endogenous Metabolite (1) Enterovirus (1) Epigenetic Reader Domain (3) ERK (4) Estrogen Receptor/ERR (1) FGFR (1) Flavivirus (1) FLT3 (9) Fungal (2) Glutathione Peroxidase (1) GSK-3 (28) HDAC (4) Histone Demethylase (1) HIV (7) HSV (4) IKK (1) Interleukin Related (1) IRE1 (1) Isotope-Labeled Compounds (1) JAK (6) JNK (3) Ligands for Target Protein for PROTAC (5) Lipoxygenase (1) MAPKAPK2 (MK2) (2) MDM-2/p53 (1) MEK (2) Microtubule/Tubulin (1) Molecular Glues (3) mTOR (2) Necroptosis (1) NF-κB (1) p38 MAPK (1) Parasite (3) PARP (2) PDGFR (1) Phosphatase (2) PI3K (5) Pim (2) PKA (1) PKC (4) PKD (1) Polo-like Kinase (PLK) (1) PPAR (3) PROTACs (8) Proton Pump (2) Raf (2) Reactive Oxygen Species (2) Reverse Transcriptase (1) ROS Kinase (1) SARS-CoV (1) SHP2 (1) SphK (2) Src (4) STAT (4) Tau Protein (1) TOPK (1) Topoisomerase (2) Trk Receptor (1) VEGFR (5) Virus Protease (1) Wnt (3) β-catenin (2)
By Research Areas:	Cancer (403) Cardiovascular Disease (2) Infection (15) Inflammation/Immunology (18) Metabolic Disease (9) Neurological Disease (19)
Click Chemistry:	Alkynes (3)

Targets Recommended: CDK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13033

CDK-IN-2

1 Publications Verification

CDK Inhibitor II
CDK Cancer

CDK-IN-2 is a potent and specific CDK9 inhibitor with IC50 of <8 nM, extracted from reference 1, example 4.
HY-112462

Cdk1/2 Inhibitor III

CDK Cancer

Cdk1/2 Inhibitor III is a selective Cdk1/2 inhibitor, with an IC₅₀ of 2.1 μM for CDK1/cyclin B .

CDK-IN-2 1 Publications Verification CDK Inhibitor II	CDK	Cancer
CDK-IN-2 is a potent and specific CDK9 inhibitor with IC50 of <8 nM, extracted from reference 1, example 4.

Cdk1/2 Inhibitor III	CDK	Cancer
Cdk1/2 Inhibitor III is a selective *Cdk1/2* inhibitor, with an IC₅₀ of 2.1 μM for CDK1/cyclin B .

HY-124639

CDK9 inhibitor HH1	CDK	Cancer
CDK9 inhibitor HH1 is a potent and selectively *CDK9* inhibitor. CDK9 inhibitor HH1 inhibits the transcription of CDK. CDK9 inhibitor HH1 can be used in research of cancer .

HY-123772

CDK5 inhibitor 20-223	CDK	Cancer
CDK5 inhibitor 20-223 is a potent *CDK2* and *CDK5* inhibitor with IC₅₀s of 6.0 and 8.8 nM, respectively. CDK5 inhibitor 20-223 is an effective anti-colorectal cancer (CRC) agent .

HY-112280

Crozbaciclib

CDK4/6/1 Inhibitor
CDK Cancer

Crozbaciclib (CDK4/6/1 Inhibitor) is a CDK4/6 inhibitor with IC₅₀s of 3 and 1 nM, respectively.

Crozbaciclib CDK4/6/1 Inhibitor	CDK	Cancer
Crozbaciclib (CDK4/6/1 Inhibitor) is a *CDK4/6* inhibitor with IC₅₀s of 3 and 1 nM, respectively.

HY-15339

CVT-313 4 Publications Verification CDK2 Inhibitor III	CDK	Cancer
CVT-313 (Cdk2 Inhibitor III) is a potent, selective, reversible, and ATP-competitive inhibitor of *CDK2* with IC₅₀ of 0.5 μM. CVT-313 inhibits CDC5L phosphorylation .

HY-157297

CDK-IN-13	CDK	Cancer
CDK-IN-13 (compound 32E) is a potent and selective inhibitor of *CDK12/cyclinK* with an IC₅₀ of 3 nM. CDK-IN-13 inhibits the growth of the HER2-positive breast cancer cell lines .

HY-50914

AZD5597

CDK Cancer

AZD5597 is an inhibitor of CDK with an IC₅₀ of 2 nM. AZD5597 has potent anti-proliferative effects against a range of cancer cell lines .

AZD5597	CDK	Cancer
AZD5597 is an inhibitor of *CDK* with an IC₅₀ of 2 nM. AZD5597 has potent anti-proliferative effects against a range of cancer cell lines .

HY-116035

Nimbolide 1 Publications Verification	NF-κB CDK Apoptosis	Cancer
Nimbolide is a triterpene compound that can be isolated from neem (Azadirachta indica), possesses anticancer and antiproliferative activity. Nimbolide induces tumor cell apoptosis by inhibiting NF-κB and *CDK4/CDK6* kinase. Nimbolide suppresses the Wnt, PI3K-Akt, MAPK and JAK-STAT signaling pathways .

HY-112371

(S)-CR8	CDK	Cancer
(S)-CR8 is the S-isomer of CR8. (S)-CR8 is a potent and selective *CDK* inhibitor with IC₅₀s of 0.060, 0.080, 0.11, 0.12, and 0.15 μM for CDK2/cyclin E, CDK2/cyclin A, CDK9/cyclin T, CDK5/p25, and CDK1/cyclin B, respectively. (S)-CR8 reduces SH-SY5Y cells survival (IC₅₀ 0.40 μM) .

HY-126244

CDK4/6-IN-3	CDK	Cancer
CDK4/6-IN-3 is a brain-penetrant *CDK4/CDK6* inhibitor with K_is of <0.3 nM and 2.2 nM, respectively. CDK4/6-IN-3 inhibits CDK1 with a K_i of 110 nM. CDK4/6-IN-3 can be used for the treatment of glioblastoma .

HY-46568

CDK7/12-IN-1	CDK	Cancer
CDK7/12-IN-1 is a selective *CDK7/12* inhibitor with IC₅₀s of 3 and 277 nM for CDK7 and CDK 12, respectively. CDK7 and CDK12 inhibition is an effective strategy to inhibit tumour growth .

HY-153336

CDK-IN-12

CDK Cancer

CDK-IN-12 (Example 20) is a CDK Inhibitor. CDK-IN-12 Inhibits CDK4/6 with IC₅₀ values less than 20 nM .

CDK-IN-12	CDK	Cancer
CDK-IN-12 (Example 20) is a CDK Inhibitor. CDK-IN-12 Inhibits CDK4/6 with IC₅₀ values less than 20 nM .

HY-130001

CDK9-IN-9	CDK	Cancer
CDK9-IN-9 (example 2) is a potent and selective *CDK9* inhibitor with an IC₅₀ of 1.8 nM. CDK9-IN-9 inhibits CDK2 with an IC₅₀ of 155 nM. CDK9-IN-9 has anti-cancer activity .

HY-145408

CDK7/9-IN-1	CDK	Cancer
CDK7/9-IN-1 is a cyclin-dependent kinases 7/9 (CDK7/9) inhibitor. CDK7/9-IN-1 selectively inhibits CDK7 over CDK9. CDK7/9-IN-1 inhibits CDK7 with IC₅₀s of 0.0656 μM and 0.00574 μM without pre-incubation and after 3 hours pre-incubation, respectively. CDK7/9-IN-1 inhibits CDK9 with an IC₅₀ of 2.14 μM after 3 hours pre-incubation. CDK7/9-IN-1 can be used for the research of cancer .

HY-112626

CDK12-IN-2	CDK	Cancer
CDK12-IN-2 is a potent, selective and nanomolar *CDK12* inhibitor (IC₅₀=52 nM) with good physicochemical properties. CDK12-IN-2 is also a strong CDK13 inhibitor due to CDK13 is the closest homologue of CDK12. CDK12-IN-2 shows excellent kinase selectivity for CDK12 over CDK2, 9, 8, and 7. CDK12-IN-2 inhibits the phosphorylation of Ser2 in the C-terminal domain of RNA polymerase II. CDK12-IN-2 can be used an excellent chemical probe for functional studies of CDK12 .

HY-10006

Flavopiridol Hydrochloride 30+ Cited Publications Alvocidib Hydrochloride; L86-8275 Hydrochloride; HMR-1275 Hydrochloride	CDK Autophagy HIV	Cancer
Flavopiridol Hydrochloride (Alvocidib Hydrochloride) is a broad inhibitor of *CDK, competing with ATP to inhibit* CDKs including CDK1, CDK2, CDK4 with IC₅₀s of 30, 170, 100 nM, respectively.

HY-151409

CDK1-IN-5	CDK	Cancer
CDK1-IN-5 (10h) is a selective *CDK1* inhibitor with IC₅₀s of 42.19, 188.71 and 354.15 nM for CDK1, CDK2 and CDK5, respectively. CDK1-IN-5 inhibits growth of cancer cells by affecting cell cycle. CDK1-IN-5 can be used for the research of cancer .

HY-151407

CDK1-IN-3	CDK	Cancer
CDK1-IN-3 (8g) is a selective *CDK1* inhibitor with IC₅₀s of 36.8, 305.17 and 369.37 nM for CDK1, CDK2 and CDK5, respectively. CDK1-IN-3 inhibits the growth of cancer cells by affecting cell cycle. CDK1-IN-3 can be used for the research of cancer .

HY-112418

CDK4/6-IN-18

CDK Cancer

CDK4/6-IN-18 (Example 2BrIC) is a selective CDK4/6 inhibitor. CDK4/6-IN-18 inhibits ionizing radiation (IR)-induced DNA damage in cells .

CDK4/6-IN-18	CDK	Cancer
CDK4/6-IN-18 (Example 2BrIC) is a selective *CDK4/6* inhibitor. CDK4/6-IN-18 inhibits ionizing radiation (IR)-induced DNA damage in cells .

HY-151463

CDK8-IN-11	CDK β-catenin	Cancer
CDK8-IN-11 is a potent and selective *CDK8* inhibitor with an IC₅₀ value of 46 nM. CDK8-IN-11 inhibits WNT/β-catenin signaling pathway. CDK8-IN-11 can be used in the research of colon cancer .

HY-151463A

CDK8-IN-11 hydrochloride	CDK β-catenin	Cancer
CDK8-IN-11 hydrochloride is a potent and selective *CDK8* inhibitor with an IC₅₀ value of 46 nM. CDK8-IN-11 hydrochloride inhibits WNT/β-catenin signaling pathway. CDK8-IN-11 hydrochloride can be used in the research of colon cancer .

HY-11009

CGP60474 5 Publications Verification	CDK PKC	Cancer
CGP60474, a highly potent anti-endotoxemic agent, is a potent cyclin-dependent kinase (CDK) inhibitor (IC₅₀ values are 26, 3, 4, 216, 10, 200 and 13 nM for CDK1/B, CDK2/E, CDK2/A, CDK4/D, CDK5/p25, CDK7/H and CDK9/T, respectively). CGP60474 is a selective and ATP-competitive PKC inhibitor .

HY-153950

CDK7-IN-22

CDK Cancer

CDK7-IN-22 (compound 101) is an CDK7 inhibitor with antitumor activity. CDK7-IN-22 shows selectivity on CDK7 .
HY-13914

Roniciclib

BAY 1000394
CDK Cancer

Roniciclib is an orally bioavailable pan-cyclin dependent kinase (CDK) inhibitor, with IC₅₀s of 5-25 nM for CDK1, CDK2, CDK3, CDK4, CDK7 and CDK9.

CDK7-IN-22	CDK	Cancer
CDK7-IN-22 (compound 101) is an *CDK7* inhibitor with antitumor activity. CDK7-IN-22 shows selectivity on CDK7 .

Roniciclib BAY 1000394	CDK	Cancer
Roniciclib is an orally bioavailable pan-cyclin dependent kinase *(CDK)* inhibitor, with IC₅₀s of 5-25 nM for CDK1, CDK2, CDK3, CDK4, CDK7 and CDK9.

HY-151408

CDK1-IN-4	CDK	Cancer
CDK1-IN-4 (10d) is a selective *CDK1* inhibitor with IC₅₀s of 44.52, 624.93 and 135.22 nM for CDK1, CDK2 and CDK5, respectively. CDK1-IN4 inhibits the growth of cancer cells by affecting cell cycle. CDK1-IN-4 can be used for the research of cancer .

HY-18299A

Purvalanol A 2 Publications Verification NG-60	CDK Autophagy Apoptosis	Cancer
Purvalanol A is a potent *CDK* inhibitor, which inhibits cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, cdk4-cyclin D1, and cdk5-p35 with IC₅₀s of 4, 70, 35, 850, 75 nM, resepctively.

HY-160171

CDK9-IN-31

CDK Cancer

CDK9-IN-31 (Compound Z1) is a CDK9 inhibitor that inhibits cancer cell growth. CDK9-IN-31 has the potential to be developed as an anticancer agent .
HY-160284

CDK12/13-IN-1

CDK Cancer

CDK12/13-IN-1 (Compound 4) is a CDK12/13 inhibitor. CDK12/13-IN-1 has antitumor activity .

CDK9-IN-31	CDK	Cancer
CDK9-IN-31 (Compound Z1) is a *CDK9* inhibitor that inhibits cancer cell growth. CDK9-IN-31 has the potential to be developed as an anticancer agent .

CDK12/13-IN-1	CDK	Cancer
CDK12/13-IN-1 (Compound 4) is a *CDK12/13* inhibitor. CDK12/13-IN-1 has antitumor activity .

HY-145424

CDK7-IN-10	CDK	Others
CDK7-IN-10 is a *CDK7* inhibitor with an IC₅₀ of less than 100 nM, extracted from patent WO2021016388A1, compound I-1. CDK7-IN-10 is useful in inhibiting the activity of a kinase. CDK7-IN-10 has the potential of inhibiting cell growth and inducing cell apoptosis .

HY-151878

CDK7-IN-20	CDK GSK-3	Metabolic Disease
CDK7-IN-20 is a potent, selective and irreversible *CDK7* (CDK) inhibitor with an IC₅₀ value of 4 nM. CDK7-IN-20 displays >206-fold selectivity for CDK7 over CDK1, CDK2, CDK3, CDK5, CDK6, CDK9 and CDK12 . CDK7-IN-20 has the potential for autosomal dominant polycystic kidney disease (ADPKD) research .

HY-10005

Flavopiridol 30+ Cited Publications HMR-1275; Alvocidib; L86-8275	CDK Autophagy HIV Apoptosis	Cancer
Flavopiridol (Alvocidib) is a broad spectrum and competitive inhibitor of *CDKs, inhibiting* CDK1, CDK2, CDK4 with IC₅₀s of 30, 170, 100 nM, respectively.

HY-117203A

CDK12-IN-E9	CDK	Cancer
CDK12-IN-E9 is a potent and selective covalent *CDK12* inhibitor and a non-covalent *CDK9* inhibitor, while avoiding ABC transporter-mediated efflux. CDK12-IN-E9 has weak binding ability to CDK7/CyclinH complex with an IC₅₀> 1 μM .

HY-139450

PF-07220060 CDK4/6-IN-6	CDK	Cancer
PF-07220060 (CDK4/6-IN-6; example A94) is a potent *CDK4/CDK6* inhibitor with a K_i of 0.6 nM and 13.9 nM for CDK4/Cyclin D1 and CDK6/Cyclin D3, respectively .

HY-147905

CDK9-IN-18	CDK Apoptosis	Cancer
CDK9-IN-18 is a potent *CDK9* inhibitor. CDK9-IN-18 blocks the phosphorylation function of kinase CDK9. CDK9-IN-18 exhibits both good anticancer activity and low cellular activity. CDK9-IN-18 induces apoptosis.

HY-160171A

CDK9-IN-31 dimaleate	CDK	Cancer
CDK9-IN-31 dimaleate (Compound Z1) is a *CDK9* inhibitor that inhibits cancer cell growth. CDK9-IN-31 dimaleate has the potential to be developed as an anticancer agent .

HY-50943

AT7519 Hydrochloride 10+ Cited Publications	CDK Apoptosis	Cancer
AT7519 Hydrochloride is a potent inhibitor of *CDKs, with IC₅₀s of 210, 47, 100, 13, 170, and <10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK*9, respectively.

HY-130852

CDK9-IN-11

CDK Ligands for Target Protein for PROTAC Cancer

CDK9-IN-11 is a potent CDK9 inhibitor. CDK9-IN-11 is the ligand for the PROTAC CDK9 Degrader-1 (HY-103628) .
HY-130850

CDK9-IN-10

CDK Ligands for Target Protein for PROTAC Cancer

CDK9-IN-10 is a potent CDK9 inhibitor. CDK9-IN-10 is the ligand for the PROTAC CDK9 degrader-2 (HY-112811) .

CDK9-IN-11	CDK Ligands for Target Protein for PROTAC	Cancer
CDK9-IN-11 is a potent *CDK9* inhibitor. CDK9-IN-11 is the ligand for the PROTAC CDK9 Degrader-1 (HY-103628) .

CDK9-IN-10	CDK Ligands for Target Protein for PROTAC	Cancer
CDK9-IN-10 is a potent *CDK9* inhibitor. CDK9-IN-10 is the ligand for the PROTAC CDK9 degrader-2 (HY-112811) .

HY-153088

CDK4/6-IN-16	CDK	Cancer
CDK4/6-IN-16 (example 195) is a potent *CDK4* and *CDK6* inhibitor, with an IC₅₀ of 0.013 μM for *CDK4. CDK4/6-IN-16 can be used for the research of CDK*4-mediated disorders, such as cancer .

HY-147131

CDK9-IN-30

CDK HIV Infection

CDK9-IN-30 is a CDK9 inhibitor that inhibits HIV-1 viral replication .

CDK9-IN-30	CDK HIV	Infection
CDK9-IN-30 is a CDK9 inhibitor that inhibits HIV-1 viral replication .

HY-149641

CDK9-IN-29	CDK	Cancer
CDK9-IN-29 (compound Z11) is a potent *CDK9* inhibitor (IC₅₀ = 3.20 nM) with good kinase selectivity. CDK9-IN-29 inhibits cell proliferation and induces apoptosis .

HY-139725

CDK5-IN-1

CDK Metabolic Disease

CDK5-IN-1, a potent CDK5 inhibitor, is against CDK5 activity less than 10 nM. CDK5-IN-1 is used for kidney diseases research .

CDK5-IN-1	CDK	Metabolic Disease
CDK5-IN-1, a potent *CDK5* inhibitor, is against CDK5 activity less than 10 nM. CDK5-IN-1 is used for kidney diseases research .

HY-144175

CDK7-IN-12	CDK	Cancer
CDK7-IN-12 is a potent inhibitor of *CDK7. CDK7-IN-12 plays a key role in transcriptional regulation and cell cycle regulation. CDK7-IN-12 effectively inhibit* malignant tumor proliferation in vitro and in vivo. CDK7-IN-12 has the potential for the research of cancer disease (extracted from patent WO2021249417A1, compound 43) .

HY-112272A

Lerociclib dihydrochloride 1 Publications Verification G1T38 dihydrochloride	CDK	Cancer
Lerociclib dihydrochloride (G1T38 dihydrochloride) is a potent and selective inhibitor of *CDK4/CDK6*, with IC₅₀s of 1 nM and 2 nM for *CDK4/CyclinD1* and *CDK6/CyclinD3*, respectively.

HY-145655

CDK7-IN-11	CDK	Cancer
CDK7-IN-11 is an orally active *CDK7* inhibitor. CDK7-IN-11 exhibits high CDK7 inhibitory activity with IC₅₀ value of 4.2 nM. CDK7-IN-11 can be effectively used for the research of diseases associated with CDK7 .

HY-111427

CDK8/19-IN-1	CDK	Cancer
CDK8/19-IN-1 is a potent, selective and oral bioavailable *CDK8/19* dual inhibitor, with IC₅₀s of 0.46 nM, 0.99 nM and 270 nM for CDK8, CDK19 and CDK9, respectively.

HY-144810

CDK2-IN-8	CDK	Cancer
CDK2-IN-8 is a potent *CDK2* inhibitor with an IC₅₀ of 1.74 µM. CDK2-IN-8 shows antiproliferative activity. CDK2-IN-8 has the potential for the research of melanoma .

HY-115992

CDK4/6-IN-9	CDK	Cancer
CDK4/6-IN-9 (compound 10) is a selective *CDK4/6* inhibitor with an IC₅₀ of 905 nM for CDK6/cyclin D1. CDK4/6-IN-9 has the potential for multiple myeloma (MM) research .

HY-11001

PHA-793887 3 Publications Verification	CDK Apoptosis	Cancer
PHA-793887 is a potent, ATP-competitive *CDK* inhibitor, can inhibit Cdk2, Cdk1, Cdk4, and Cdk9 with IC₅₀s of 8 nM, 60 nM, 62 nM and 138 nM, respectively, and also inhibits glycogen synthase kinase 3β with an IC₅₀ of 79 nM.

Cat. No.	Product Name

HY-L009

Kinase Inhibitor Library

2673 compounds

Kinase is an enzyme that adds phosphate groups to other molecules. This process is known as phosphorylation. Protein phosphorylation is a key aspect in the regulation of a large number of cellular processes including cellular division, metabolism, signal transduction, and so on. There are over 500 kinases encoded by the human genome and it has been estimated that kinases regulate approximately 50% of cellular functions. Kinases are a large group of drug targets in drug discovery. Kinase inhibitors are an important class of drugs that block certain enzymes involved in diseases such as cancer and inflammatory disorders.

Kinase inhibitor library designed by MCE contains 2673 kinase inhibitors and regulators mainly targeting protein kinases (VEGFR, EGFR, BTK, CDK, Akt, etc.), lipid kinases (PI3K, PI4K, SK, etc.) and carbohydrate kinases (Hexokinase), and is a useful tool for kinase drug discovery and related research.

Cat. No.	Product Name	Target	Research Area

HY-P3730

Cdk2/Cyclin Inhibitory Peptide I

CDK Cancer

Cdk2/Cyclin Inhibitory Peptide I (Tat-LFG), a CDK2 inhibitor, kills U2OS osteosarcoma cells in a dose-dependent manner .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-116035

Nimbolide 1 Publications Verification	Triterpenes Structural Classification Classification of Application Fields Terpenoids Source classification Plants Azadirachta indica A. Juss. Disease Research Fields Meliaceae Cancer	NF-κB CDK Apoptosis
Nimbolide is a triterpene compound that can be isolated from neem (Azadirachta indica), possesses anticancer and antiproliferative activity. Nimbolide induces tumor cell apoptosis by inhibiting NF-κB and *CDK4/CDK6* kinase. Nimbolide suppresses the Wnt, PI3K-Akt, MAPK and JAK-STAT signaling pathways .

HY-103248

Toyocamycin 4 Publications Verification Vengicide	Infection Structural Classification Microorganisms Classification of Application Fields Antibiotics Source classification Antibacterial Disease Research Disease Research Fields Other Antibiotics	IRE1 Fungal Antibiotic Apoptosis CDK
Toyocamycin (Vengicide) is an adenosine analog produced by Streptomyces diastatochromogenes, acts as an XBP1 inhibitor. Toyocamycin blocks RNA synthesis and ribosome function, and induces apoptosis. Toyocamycin affects IRE1α-XBP1 pathway, and inhibits XBP1 mRNA cleavage with an IC₅₀ value of 80 nM with affecting IRE1α auto-phosphorylation. Toyocamycin specifically inhibits *CDK9* with an IC₅₀ value of 79 nM .

HY-W010128

6-(Dimethylamino)purine 6-Dimethylaminopurine	Classification of Application Fields Other Diseases Disease Research Fields	CDK
6-(Dimethylamino)purine is a dual inhibitor of protein kinase and *CDK* .

HY-N5072

Desmethylglycitein 4',6,7-Trihydroxyisoflavone	Flavonoids Classification of Application Fields Leguminosae Glycine max (L.) merr Source classification Phenols Polyphenols Plants Disease Research Fields Isoflavones Cancer	CDK PI3K PKC
Desmethylglycitein (4',6,7-Trihydroxyisoflavone), a metabolite of daidzein, sourced from Glycine max with antioxidant, and anti-cancer activities. Desmethylglycitein binds directly to *CDK1* and *CDK2* in vivo, resulting in the suppresses CDK1 and CDK2 activity . Desmethylglycitein is a direct inhibitor of protein kinase C (PKC)α, against solar UV (sUV)-induced matrix matrix metalloproteinase 1 (MMP1) . Desmethylglycitein binds to PI3K in an ATP competitive manner in the cytosol, where it inhibits the activity of PI3K and downstream signaling cascades, leading to the suppression of adipogenesis in 3T3-L1 preadipocytes .

HY-149436

CDK2/Bcl2-IN-1	Structural Classification Terpenoids Zygophyllaceae Source classification Diterpenoids Plants Zygophyllum album L.f.	CDK
CDK2/Bcl2-IN-1 (compound 1), a saponin and a CDK-2 inhibitor (IC₅₀=117.6 nM) with promising cytotoxicity against cancer cells. CDK2/Bcl2-IN-1 also inhibits Bcl-2, and induces apoptosis in A549 lung cancer cells .

HY-N0400

Wogonin Maximum Cited Publications 13 Publications Verification	Flavonoids Scutellaria baicalensis Georgi Classification of Application Fields Flavones Labiatae Source classification Phenols Polyphenols Plants Inflammation/Immunology Disease Research Fields	CDK Wnt Autophagy Apoptosis
Wogonin is a naturally occurring mono-flavonoid, can inhibit the activity of *CDK8* and Wnt, and exhibits anti-inflammatory and anti-tumor effects.

HY-103382

Arcyriaflavin A	Infection Alkaloids Structural Classification Microorganisms Classification of Application Fields Source classification Disease Research Fields Indole Alkaloids	Fungal
Arcyriaflavin A is a fungal metabolite obtained from the fungi, Nocardiopsis. Arcyriaflavin A is an inhibitor of CDK4 (IC₅₀ = 140 nM) and CaMKII (IC₅₀ = 25 nM) .

HY-W077292

2,4,6-Trihydroxybenzoic acid	Classification of Application Fields Ketones, Aldehydes, Acids Source classification Phenols Polyphenols Endogenous metabolite Disease Research Fields Cancer	CDK
2,4,6-Trihydroxybenzoic acid, the flavonoid metabolite, is a *CDK* inhibitor. 2,4,6-Trihydroxybenzoic acid can be used for the research of cancer .

HY-117025A

Manzamine A hydrochloride 1 Publications Verification Keramamine A hydrochloride	Structural Classification Neurological Disease Classification of Application Fields Source classification Marine natural products Pyridine Alkaloids Indole Alkaloids Infection Alkaloids Piperidine Alkaloids Animals Sponge Disease Research Fields	GSK-3 CDK Parasite Proton Pump HSV Autophagy
Manzamine A hydrochloride, an orally active beta-carboline alkaloid, inhibits specifically GSK-3β and *CDK-5* with IC₅₀s of 10.2 μM and 1.5 μM, respectively. Manzamine A hydrochloride targets vacuolar ATPases and inhibits autophagy in pancreatic cancer cells. Manzamine A hydrochloride has antimalarial and anticancer activities. Manzamine A hydrochloride also shows potent activity against HSV-1 .

HY-117025

Manzamine A Keramamine A	Infection Alkaloids Structural Classification Neurological Disease Classification of Application Fields Animals Marine natural products Sponge Disease Research Fields Cancer	GSK-3 CDK Parasite Proton Pump HSV Autophagy
Manzamine A, an orally active beta-carboline alkaloid, inhibits specifically GSK-3β and *CDK-5* with IC₅₀s of 10.2 μM and 1.5 μM, respectively. Manzamine A targets vacuolar ATPases and inhibits autophagy in pancreatic cancer cells. Manzamine A has antimalarial and anticancer activities. Manzamine A also shows potent activity against HSV-1 .

HY-N3634

Corylifol C	Structural Classification Leguminosae Source classification Phenols Polyphenols Psoralea corylifolia L. Plants	Others
Corylifol C is a potent protein kinase inhibitor with IC₅₀ valueS of 8.7, 3.0, 2.1, 6.4, 4.5, 6.2, 2.3, 1.2, 5.1 μg/ml for ARK5, Aurora-A, Aurora-B, AXL, B-RAF-VE, CDK4/CycD1, TIE2, EGF-R, EPHB4, respectively .

HY-N1127

Tricin 1 Publications Verification	Infection Structural Classification Flavonoids Classification of Application Fields Flavones Source classification Agrostidoideae Phenols Polyphenols Plants Disease Research Fields Triticum aestivum L.	CMV
Tricin is a natural flavonoid found in large amounts in wheat. Tricin inhibits HCMV replication by inhibiting CDK9. Tricin inhibits the proliferation and invasion of C6 glioma cells by upregulating the expression of FAK-targeting microRNA-7 .

HY-N0400R

Wogonin (Standard)	Structural Classification Flavonoids Scutellaria baicalensis Georgi Classification of Application Fields Labiatae Source classification Phenols Plants Inflammation/Immunology Disease Research Fields	CDK Wnt Autophagy Apoptosis
Wogonin (Standard) is the analytical standard of Wogonin. This product is intended for research and analytical applications. Wogonin is a naturally occurring mono-flavonoid, can inhibit the activity of *CDK8* and Wnt, and exhibits anti-inflammatory and anti-tumor effects.

HY-N0636

Eriocitrin 1 Publications Verification	Structural Classification Flavonoids Classification of Application Fields Citrus limon (L.) Burm. F. Flavonones Source classification Rutaceae Phenols Polyphenols Plants Disease Research Fields Cancer	Apoptosis
Eriocitrin is a flavonoid isolated from lemons that is a powerful antioxidant. Eriocitrin inhibits the proliferation of liver cancer cells by arresting the cell cycle in the S phase by upregulating p53, cyclin A, cyclin D3 and CDK6. Eriocitrin triggers apoptosis by activating intrinsic signaling pathways involving mitochondria .

HY-N11439

Albanol B	Structural Classification Natural Products Source classification Phenols Polyphenols Morus alba L. Plants Moraceae	CDK Akt ERK Apoptosis Bacterial
Albanol B is an arylbenzofuran derivative which can be isolated from mulberries. Albanol B exhibits anti-Alzheimer's disease, anti-bacterial and antioxidant activities. Albanol B inhibits cancer cells proliferation, down-regulates *CDK1* expression. Albanol B also induces cell cycle arrest at G2/M and apoptosis. And Albanol B induces mitochondrial ROS production and increases the phosphorylation levels of AKT and ERK1/2 .

HY-W019806

Lacto-N-fucopentaose I LNFP I	Infection Structural Classification Natural Products Polysaccharides Classification of Application Fields Animals Inflammation/Immunology Disease Research Fields Saccharides	Endogenous Metabolite CDK Reactive Oxygen Species Apoptosis Enterovirus Bacterial
Lacto-N-fucopentaose I (LNFPI) is a human milk oligosaccharide (HMO), possessing antiviral and antibacterial activity. Lacto-N-fucopentaose I can reduce capsid protein VP1 to block virus adsorption, promote *CDK2* and reduce cyclin E to recover cell cycle S phase block. Lacto-N-fucopentaose I inhibits ROS production and apoptosis in virus-infected cells. Lacto-N-fucopentaose I can also regulate intestinal microbiota to affect immune system development .

HY-N6954

Garcinone C 1 Publications Verification	Structural Classification other families Xanthones Classification of Application Fields Garcinia oblongifolia Champ. ex Benth. Source classification Guttiferae Phenols Polyphenols Plants Disease Research Fields Cancer	ATM/ATR STAT CDK
Garcinone C, a xanthone derivative, is a natural compound extracted from Garcinia oblongifolia that is used as an anti-inflammatory, astringency and granulation-promoting medicine, and has potential cytotoxic effects on certain cancers. Garcinone C stimulates the expression levels of ATR and 4E-BP1, while efficiently inhibiting the expression levels of cyclin B1, cyclin D1, cyclin E2, cdc2, Stat3 and *CDK7. Garcinone C significantly inhibits* cell viability of the human Nasopharyngeal carcinoma (NPC) cell lines CNE1, CNE2, HK1 and HONE1 in a time‑ and dose‑dependent manner .

Cat. No.	Compare	Product Name	Species	Source

HY-P72785

	CDKN2A Protein, Human Cyclin-dependent kinase Inhibitor 2A; CDK4I; MTS-1; p16INK4A	Human	E. coli
	CDKN2A Protein, a potent negative regulator of cell proliferation, forms strong interactions with CDK4 and CDK6, hindering their association with cyclins D and retinoblastoma protein phosphorylation. Acting in a heterodimeric manner, predominantly with CDK6, CDKN2A inhibits cyclin D-CDK4 kinase activity and interacts with ISCO2, contributing to its cell cycle regulatory role. CDKN2A Protein, Human is the recombinant human-derived CDKN2A protein, expressed by E. coli , with tag free. The total length of CDKN2A Protein, Human is 155 a.a., with molecular weight of ~19.12 kDa.

Cat. No.	Product Name	Chemical Structure

HY-16297AS

Abemaciclib-d8
Abemaciclib-d₈ is the deuterium labeled Abemaciclib. Abemaciclib (LY2835219) is a selective CDK4/6 inhibitor with IC50 values of 2 nM and 10 nM for CDK4 and CDK6, respectively.

HY-15777AS

Ribociclib-d6 hydrochloride
Ribociclib-d₆ (hydrochloride) is a deuterium labeled Ribociclib. Ribociclib is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex[1].

HY-15777S1

Ribociclib-d8
Ribociclib-d₈ is the deuterium labeled Ribociclib[1]. Ribociclib (LEE01) is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex[2].

HY-151580S

CDK2-IN-14-d3

CDK2-IN-14-d₃ is a potent and selective CDK2 inhibitor. CDK2-IN-14-d₃ can be used in research of cancer[1].

HY-15777S

Ribociclib-d6
Ribociclib-d₆ is a deuterium labeled Ribociclib. Ribociclib is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex[1].

HY-129336S

Abemaciclib metabolite M20-d8
Abemaciclib metabolite M20-d₈ is the deuterium labeled Abemaciclib metabolite M20. Abemaciclib metabolite M20 (LSN3106726), the active metabolite of Abemaciclib, is a selective CDK4/6 inhibitor[1].

HY-126534S

Abemaciclib metabolite M18-d8
Abemaciclib metabolite M18-d₈ is the deuterium labeled Abemaciclib metabolite M18. Abemaciclib metabolite M18 (LSN3106729), the metabolite of Abemaciclib (HY-16297A), is a CDK inhibitor with antitumor activity. Abemaciclib metabolite M18 and a CRBN ligand have been used to design PROTAC CDK4/6 degrader[1][2].

HY-50767S

Palbociclib-d8
Palbociclib-d₈ is a deuterium labeled Palbociclib. Palbociclib is a selective and orally active CDK4 and CDK6 inhibitor with IC50s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research[1].

HY-50767S1

Palbociclib-d4 hydrochloride
Palbociclib-d₄ (hydrochloride) is the deuterium labeled Palbociclib hydrochloride. Palbociclib (PD 0332991) is a selective CDK4 and CDK6 inhibitor with IC50s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research[1].

HY-128669S

Abemaciclib metabolite M2-d6
Abemaciclib metabolite M2-d₆ is the deuterium labeled Abemaciclib metabolite M2. Abemaciclib metabolite M2 (LSN2839567) is a metabolite of Abemaciclib, acts as a potent CDK4 and CDK6 inhibitor, with IC50s in the range of 1-3 nM. Anti-cancer activity[1][2].

HY-N1127S

Tricin-d6
Tricin-d₆ is the deuterium labeled Tricin[1]. Tricin is a natural flavonoid present in large amounts in Triticum aestivum. Tricin can inhibit human cytomegalovirus (HCMV) replication by inhibiting CDK9. Tricin inhibits the proliferation and invasion of C6 glioma cells via the upregulation of focal-adhesion-finase (FAK)-targeting microRNA-7[2][3][4].

Cat. No.	Product Name	Application	Reactivity

HY-P80774

p21 Antibody CDKN1A; CAP20; CDKN1; CIP1; MDA6; PIC1; SDI1; WAF1; Cyclin-dependent kinase Inhibitor 1; CDK-interacting protein 1; Melanoma differentiation-associated protein 6; MDA-6; p21	WB, ICC/IF	Human, Mouse, Rat
p21 Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 18 kDa, targeting to p21. It can be used for WB,ICC/IF assays with tag free, in the background of Human, Mouse, Rat.

HY-P80773

p21 Antibody (YA254) CDKN1A; CAP20; CDKN1; CIP1; MDA6; PIC1; SDI1; WAF1; Cyclin-dependent kinase Inhibitor 1; CDK-interacting protein 1; Melanoma differentiation-associated protein 6; MDA-6; p21	WB	Human, Mouse
p21 Antibody (YA254) is a non-conjugated and Rabbit origined monoclonal antibody about 18 kDa, targeting to p21. It can be used for WB assays with tag free, in the background of Human, Mouse.

HY-P80615

CDKN2A Antibody CDKN2A; CDKN2; MTS1; Cyclin-dependent kinase Inhibitor 2A; isoforms 1/2/3; Cyclin-dependent kinase 4 Inhibitor A; CDK4I; Multiple tumor suppressor 1; MTS-1; p16-INK4a; p16-INK4; p16INK4A	WB, IP	Human, Mouse
CDKN2A Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 17 kDa, targeting to CDKN2A. It can be used for WB,IP assays with tag free, in the background of Human, Mouse.

Cat. No.	Product Name		Classification

HY-116423

JH295		Alkynes
JH295 is a potent, irreversible and selective NIMA-related kinase 2 (Nek2) inhibitor with an IC₅₀ of 770 nM. JH295 inhibits cellular Nek2 via alkylation of Cys22. JH295 is inactive against the mitotic kinases, Cdk1, Aurora B or Plk1, and does not perturb bipolar spindle assembly or the spindle assembly checkpoint . JH295 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-148213

CDK2/4/6-IN-1		Alkynes
CDK2/4/6-IN-1(example 29) is a *CDK2/4/6* inhibitor with IC₅₀ values of 2.5, 23.7 and 44.3 nM for CDK2, CDK4 and CDK6, respectively. CDK2/4/6-IN-1 can be used in cancer research . CDK2/4/6-IN-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-116423A

JH295 hydrate		Alkynes
JH295 hydrate is a potent, irreversible and selective NIMA-related kinase 2 (Nek2) inhibitor with an IC₅₀ of 770 nM. JH295 hydrate inhibits cellular Nek2 via alkylation of Cys22. JH295 hydrate is inactive against the mitotic kinases, Cdk1, Aurora B or Plk1, and does not perturb bipolar spindle assembly or the spindle assembly checkpoint . JH295 (hydrate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry